Join Aura Biosciences for a virtual urologic oncology investor event featuring key opinion leaders (KOLs) Neal Shore, MD, FACS (Carolina Urologic Research Center), Gary Steinberg, MD, FACS (Rush University) and Jennifer A. Linehan, MD (Saint John’s Cancer Institute), who will join company management to discuss additional data from the ongoing Phase 1 trial in NMIBC, a multi-center, open-label clinical trial designed as a window of opportunity study to assess the safety and feasibility of local administration of bel-sar (AU-011) as a monotherapy prior to transurethral resection of bladder tumor (TURBT), the standard of care procedure. The study is designed to evaluate different approaches to optimize the feasibility of local administration and includes histopathological evaluation after a single dose to assess bel-sar’s biological activity and dual mechanism of action including the characterization of the immune response.

At the event, Aura will also provide a bladder cancer program update, including the planned Phase 1b/2 trial expansion and future development plans.

A live question and answer session will follow the discussion.